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Abstract
Background: Intra-abdominal infections (IAIs) represent a most frequent gastrointestinal emergency and serious
cause of morbimortality. A full classification, including all facets of IAIs, does not exist. Two classifications are used
to subdivide IAIs: uncomplicated or complicated, considering infection extent; and community-acquired, healthcare-
associated or hospital-acquired, regarding the place of acquisition. Adequacy of initial empirical antibiotic therapy
prescribed is an essential need. Inadequate antibiotic therapy is associated with treatment failure and increased
mortality. This study was designed to determine accuracy of different classifications of IAIs to identify infections by
pathogens sensitive to current treatment guidelines helping the selection of the best antibiotic therapy.
Methods: A retrospective cohort study including all adult patients discharged from hospital with a diagnosis of IAI
between 1st of January and 31st of October, 2016. All variables potentially associated with pre-defined outcomes:
infection by a pathogen sensitive to non-pseudomonal cephalosporin or ciprofloxacin plus metronidazole (ATB 1,
primary outcome), sensitive to piperacillin-tazobactam (ATB 2) and hospital mortality (secondary outcomes) were
studied through logistic regression. Accuracy of the models was assessed by area under receiver operating
characteristics (AUROC) curve and calibration was tested using the Hosmer-Lemeshow goodness-of-fit test.
Results: Of 1804 patients screened 154 met inclusion criteria. Sensitivity to ATB 1 was independently associated with
male gender (adjusted OR = 2.612) and previous invasive procedures in the last year (adjusted OR = 0.424) (AUROC
curve = 0,65). Sensitivity to ATB 2 was independently associated with liver disease (adjusted OR = 3.580) and post-
operative infections (adjusted OR = 2.944) (AUROC curve = 0.604). Hospital mortality was independently associated with
age≥ 70 (adjusted OR = 4.677), solid tumour (adjusted OR = 3.127) and sensitivity to non-pseudomonal cephalosporin
or ciprofloxacin plus metronidazole (adjusted OR = 0.368).
The accuracy of pre-existing classifications to identify infection by a pathogen sensitive to ATB 1 was 0.59 considering
place of acquisition, 0.61 infection extent and 0.57 local of infection, for ATB 2 it was 0.66, 0.50 and 0.57, respectively.
Conclusion: None of existing classifications had a good discriminating power to identify IAIs caused by pathogens
sensitive to current antibiotic treatment recommendations. A new classification, including patients’ individual
characteristics like those included in the current model, might have a higher potential to distinguish IAIs by resistant
pathogens allowing a better choice of empiric antibiotic therapy.
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Background
Intra-abdominal infections (IAIs) represent one of the
most frequent gastrointestinal emergencies and a serious
cause of morbidity and mortality [1–6]. A full classifica-
tion that includes all facets of IAIs does not exist. An opti-
mal classification designed for clinicians’ guidance in
treatment should include: the origin of the source of infec-
tion, the anatomical extension, the supposed pathogens
involved and risk factors for major resistance patterns,
and the clinical condition of the patient [2, 6, 7].
IAIs are most frequently subdivided as uncomplicated or
complicated, considering the extent of infection [1, 2, 6–11].
An uncomplicated intra-abdominal infection (uIAI) is an
infection that involves a single organ and does not extend to
the peritoneum [1, 2, 4–13]. A complicated intra-abdominal
infection (cIAI) extends beyond a single organ into the
peritoneal space [1, 2, 4–13].
Based on place of acquisition, infections are divided in:
community-acquired intra-abdominal infection (CA-IAI)
as an infection present at hospital admission or within
48 h in patients that did not meet the criteria for
healthcare-associated infection and it is usually caused
by the patient’s own flora [3, 6, 9, 12–15], hospital-
acquired intra-abdominal infections (HA-IAIs), defined
as infections that were not present at the time of
hospital admission but emerge as noticeable after at least
48 h in patients hospitalized for other purpose than IAIs
[12, 15–17], and healthcare-associated infections (HCA-
IAIs) [18, 19], defined as infections present at hospital
admission or within 48 h of admission in patients with
previous contact with healthcare, namely invasive proce-
dures, or that resides in a long-term care facility [12, 18].
The adequacy of initial empirical antibiotic therapy
prescribed for IAIs is an essential need [1, 6, 9, 11, 12, 15],
due to the minimum 48 h’ time required to have micro-
biological data available [1, 6, 9, 11]. Suitable empiric anti-
biotic therapy has a huge impact on the outcome of
patients diagnosed with IAIs [12, 15, 20–22]. In CA-IAI,
antibiotics with a restricted spectrum of activity are sug-
gested [6, 9, 12, 23], such as cephalosporins without
Pseudomonas aeruginosa coverage plus metronidazole,
ciprofloxacin plus metronidazole, and piperacillin/tazo-
bactam [6, 9, 12, 24]. In HA-IAIs, antibiotic regimens with
vaster spectra of coverage are suggested [6, 9, 11].
There is evidence that inadequate and/or delayed
antibiotic therapy is associated with treatment failure
and increased mortality [1, 12, 13, 20–22, 25–30]. The
sensitive equilibrium between the enhancement of em-
pirical antibiotic therapy, which was proved to pro-
mote better clinical results, and the decline of
needless antimicrobial overuse, which has been linked
to the increasing development of multi-drug resistant
(MDR) pathogens, is invariably needed when treating
infections [6, 12, 31].
This study was designed to assess the impact of the
different classifications of IAIs in the selection of the
best antibiotic therapy, considering the need of adequate
empirical antibiotic therapy and public health need to
preserve antibiotics.
Methodology
Study design and selection
A retrospective cohort study developed at Hospital de
Santo António, Centro Hospitalar Universitário do Porto,
a tertiary care university hospital, including all adult pa-
tients (≥18 years old) discharged from the hospital with
the diagnosis of IAI between 1st of January and 31st of
October of 2016.
The main inclusion criteria were meeting the CDC defin-
ition of intra-abdominal infection (CDC. CDC/NHSN
Surveillance Definitions for Specific Types of Infections.
2018; Available from: https://www.cdc.gov/nhsn/pdfs/
pscmanual/17pscnosinfdef_current.pdf). First selection of
the patients was achieved using the International Statistical
Classification of Diseases and Related Health Problems 9th
revision (ICD-9) including those with a discharge code
compatible with intra-abdominal infection [ICD-9 codes
considered in Additional file 1]. For selected patients,
clinical file was reviewed to inclusion criteria confirmed
and data of interest retrieved [see Additional file 2].
Exclusion criteria were: patients with anal/rectal
pathology, infections caused by non-bacterial pathogens
(that is virus, fungus and protozoa), non-complicated
appendicitis, tuberculosis and patients with negative or
no culture results.
The following variables were collected: age, gender,
functional status, previous comorbidities, hospital admis-
sion date, discharge date, place of acquisition of the
infection (community-acquired, healthcare-associated or
hospital-acquired), extent of infection (uncomplicated or
complicated), localization of infection (appendix, biliary
tract, colon, small intestine, stomach/duodenum or other),
post-operative infection (perforation, suture dehiscence,
tertiary peritonitis, undetermined or non-applicable), mi-
croorganism(s) isolated, location of the isolated pathogen,
realization of blood cultures, blood cultures’ result, resist-
ance of isolated pathogens, empirical therapy administered
to the patient in the first 24 h after diagnosis (antibiotic,
daily dose, route of administration), change of the initial
antibiotic therapy, reason of the changing, adequacy of the
empirical antibiotic therapy, risk factors for healthcare-
associated infections, previous colonization/infection by
DR pathogen, previous antibiotic therapy (last 3 months),
previous hospital admission (last year), previous invasive
procedures (last year) and residence in a long-term care
facility or nursing home and outcome at hospital dis-
charge (dead or alive).
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Functional status was assessed by the Karnofsky
Performance Status Scale (KPS) [32] and previous
comorbidities by the Charlson Comorbidity Index (CCI)
[33]. The initial empirical antibiotic therapy was considered
appropriate if all of the bacteria isolated from cultures were
sensitive to at least one of the drugs administered.
The primary outcome of interest was infection by a
pathogen sensitive to the following antibiotic scheme:
non-pseudomonal cephalosporin or ciprofloxacin plus
metronidazole. Secondary outcomes were sensitivity to
piperacillin/tazobactam and hospital mortality.
Statistical analysis
Data were described by means and standard deviations
(SD) for continuous variables or with medians and inter-
quartile ranges (IQR) if they showed a skewed distribu-
tion. Categorical variables were described with absolute
frequencies and percentages. T-tests or Mann-Whitney-
U tests were used to compare continuous variables. For
categorical variables, these comparisons were performed
using Pearson χ2 and Fisher’s exact tests.
All variables potentially associated with pre-defined
outcomes were studied through logistic regression.
Those with a clear association in the univariate analysis
(p < 0.1) were included in the multivariable analysis. The
results of the multivariable models are expressed as odds
ratio (OR) with 95% confidence interval (CI95%) and p-
values. The accuracy of the models was assessed by the
area under receiver operating characteristics (AUROC)
curve and calibration was tested using the Hosmer-
Lemeshow goodness-of-fit test. The significance level
was defined as p < 0.05.
Data were analysed using the Statistical Package for
the Social Sciences (SPSS) version 25 for Windows
(SPSS Inc., Chicago, IL, USA).
Results
There were 1804 patients discharged from the hospital
during the study period that met the ICD-9 established
criteria. Of these, 154 met the inclusion criteria (Fig. 1).
Patients included in the study had a mean±SD age of
73 ± 14 years and 48% were male; 112 (73%) need some help
for daily activities defined by a KPS scale < 70 and 31 (20%)
patients had no comorbidities according to the CCI definitions
(Table 1). Median (IQR) hospital length of stay was 17 [10–
29] days and hospital mortality rate was 22% (n= 34).
The following risk factors were associated with an
IAI by pathogens sensitive to ATB 1: male gender,
previous antibiotic therapy and previous invasive pro-
cedures (Table 1). The final model retained male
gender with an adjusted OR (CI95%) = 2.612 (1.328-
5.148) and previous invasive procedures in the last
year with an adjusted OR (CI95%) = 0.424 (0.216-
0.833). The AUROC curve (CI95%) was 0.65 (0.57-
0.74) (Table 2).
Fig. 1 Flow diagram of the population selection process. (ICD-9, International Statistical Classification of Diseases and Related Health Problems
9th revision; IAI, intra-abdominal infection)
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Considering ATB 2 as the dependent variable, the final
model retained liver disease with an adjusted OR (CI95%) =
3.580 (1.126–10.879) and post-operative infections with an
adjusted OR (CI95%) = 2.944 (1.096–7.908) (Table 1). The
AUROC curve (CI95%) was 0.604 (0.504–0.704) (Table 2).
Intra-abdominal infections classification and
microbiological results
Comparison of the accuracy of different classifications of
the IAI in determining infection by a pathogen sensitive
to current treatment guidelines is shown in Table 2.
Table 1 Population’s general characteristics and risk factors for IAI by pathogens sensitive to ATB 1 or to ATB 2
Total IAI by pathogens
susceptible to ATB 1
p value IAI by pathogens
susceptible to ATB 2
p value
Age≥ 70, n (%) 101 (66) 52 (65) 0.874 72 (64) 0.253
Male gender, n (%) 74 (48) 46 (58) 0.015 49 (47) 0.614
Karnofsky Performance Status Scale < 70, n (%) 112 (73) 62 (78) 0.167 73 (70) 0.191
Diabetes, n (%) 45 (29) 19 (24) 0.121 28 (27) 0.308
Liver disease, n (%) 14 (9) 6 (8) 0.475 6 (6) 0.033
Solid tumour, n (%) 45 (29) 23 (29) 0.894 31 (30) 0.904
AIDS, n (%) 1 (1) 1 (1) 1.000a 1 (1) 1.000a
Chronic kidney disease, n (%) 26 (17) 9 (11) 0.052 18 (17) 0.900
Congestive heart failure, n (%) 11 (7) 7 (9) 0.537a 8 (8) 1.000a
Myocardial infarction, n (%) 10 (7) 7 (9) 0.331a 9 (9) 0.171a
Chronic obstructive pulmonary disease, n (%) 10 (7) 6 (8) 0.748a 8 (8) 0.504a
Peripheral vascular disease, n (%) 22 (14) 11 (14) 0.843 14 (13) 0.621
Cerebrovascular accident/transient ischemic attack, n (%) 14 (9) 8 (10) 0.683 11 (11) 0.550a
Dementia, n (%) 11 (7) 3 (4) 0.120a 7 (7) 1.000a
Hemiplegia, n (%) 1 (1) 1 (1) 1.000a 1 (1) 1.000a
Connective tissue disease, n (%) 2 (1) 1 (1) 1.000a 1 (1) 1.000a
Leukemia, n (%) 3 (2) 1 (1) 0.608a 2 (2) 1.000a
Malignant lymphoma, n (%) 1 (1) 1 (1) 1.000a 1 (1) 1.000a
Peptic ulcer disease, n (%) 4 (3) 3 (4) 0.621a 3 (3) 1.000a
Total score - Charlson Comorbidity Index, mean ± SD 5 ± 3 5 ± 3 0.744 5 ± 3 0.352
Residence in a long-term care facility or nursing home, n (%) 7 (5) 2 (3) 0.259a 4 (4) 0.681a
Previous colonization/infection by DR pathogen, n (%) 29 (19) 16 (20) 0.700 20 (19) 0.920
Previous antibiotic therapy, n (%) 39 (25) 14 (18) 0.020 22 (21) 0.068
Previous hospitalization, n (%) 82 (53) 37 (46) 0.070 51 (49) 0.089
Previous invasive procedures, n (%) 78 (51) 34 (43) 0.028 48 (46) 0.082
Post-operative Infection, n (%) 19 (12) 9 (11) 0.670 9 (9) 0.037
aFisher’s exact test; AIDS, acquired immune deficiency syndrome; ATB 1, non-pseudomonal cephalosporin or ciprofloxacin plus metronidazole; ATB 2, piperacillin/
tazobactam; DR drug-resistant, OR odds ratio, SD standard deviation
Table 2 Discriminative power of each classification for IAI by pathogen sensitive to antibiotic scheme for CA-IAI
Classification of intra-abdominal infection AUROC curve (95% CI) for ATB 1 AUROC curve (95% CI) for ATB 2
Place of acquisition: CA-IAI, HCA-IAI, HA-IAI 0.59 (0.50–0.68) 0.66 (0.56–0.75)
Place of acquisition: CA-IAI and HA-IAI 0.54 (0.45–0.63) 0.59 (0.49–0.69)
Extent of infection: uIAI or cIAI 0.61 (0.52–0.70) 0.50 (0.40–0.60)
Local of infection 0.57 (0.48–0.66) 0.57 (0.48–0.67)
Current model 0.65 (0.57–0.74) 0.60 (0.50–0.70)
AUROC area under receiver operating characteristics, CI confidence interval, ATB I, non-pseudomonal cephalosporin or ciprofloxacin plus metronidazole, ATB 2
piperacillin/tazobactam, CA-IAI community-acquired intra-abdominal infection, HCA-IAI healthcare-associated intra-abdominal infection, HA-IAI hospital-acquired
intra-abdominal infection, uIAI uncomplicated intra-abdominal infection, cIAI complicated intra-abdominal infection
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Postoperative infection was observed in 19 (12%) pa-
tients, caused by suture dehiscence in 8 (5%) patients,
perforation in 3 (2%) patients and undetermined or by
other causes in 8 (5%) patients.
Blood cultures were drawn in 122 (79%) patients at
hospital admission, of those 69 (57%) were positive. Be-
sides blood, pathogens were isolated from peritoneal
fluid in 60 (39%), bile in 13 (8%), faeces in 11 (7%),
abscess in 9 (5%), biliary drainage fluid in 1 (1%) and
pancreas drainage fluid in 1 (1%).
The microbiological profile according to different clas-
sifications is shown in Table 3.
Antibiotic therapy
Although non-pseudomonal cephalosporin or ciprofloxacin
plus metronidazole is the shorter spectrum recommended
antibiotic therapy for CA-IAI, it was administered to only
one patient, but if it was administered to all patients, it
would have been adequate in 54% of them.
Among the antibiotic agents administered, piperacil-
lin/tazobactam was the most frequently used, in 123
(80%) patients, followed by metronidazole in 7 (5%),
imipenem plus cilastatin in 6 (4%), ciprofloxacin in 5
(3%) and amoxicillin/clavulanic acid in 4 (3%). Neverthe-
less, the sensitivity to piperacillin/tazobactam was exhib-
ited in 105 (68%) patients.
The distribution of sensitive pathogens to the studied anti-
biotic regimens (non-pseudomonal cephalosporin or cipro-
floxacin plus metronidazole, or piperacillin/tazobactam),
according to the different classifications is shown in Table 3.
The empirical antibiotic therapy was changed in 83
(54%) patients, of these adjustments to the susceptibility
profile of the isolated pathogen was the most frequent
reason in 40 (48%) patients.
The initial antibiotic therapy was adequate in 98 (64%)
patients: 60 (72%) with CA-IAIs, 26 (56%) with HCA-
IAIs and 12 (46%) with HA-IAIs (p = 0.034). In uIAI, 17
(68%) patients had adequate initial antibiotic therapy
and in cIAI 81 (63%) patients (p = 0.620). There was no
relation between the local of infection and the adequacy
of the initial antibiotic therapy (p = 0.628).
In patients with post-operative infections, a higher fre-
quency of inadequate antibiotic therapy was observed
(63% vs. 33%, p = 0.010).
Table 3 Microbiological profile of IAI according to the different classifications
Place of acquisition, n (%) CA-IAI, 83 (54) HCA-IAI, 45 (29) HA-IAI, 26 (17)
Microbiological profile, n (%) Monomicrobial, 46 (55)
E. coli, 19 (41)
Klebsiella spp., 7 (15)
E. faecium, 4 (19)
Other, 16 (25)
Polymicrobial, 37 (45)
Monomicrobial, 32 (61)
E. coli, 7 (22)
Klebsiella spp., 7 (22)
Clostridium spp., 6 (19)
Other, 12 (37)
Polymicrobial, 13 (29)
Monomicrobial, 17 (65)
E. coli, 4 (24)
Klebsiella spp., 2 (12)
E. faecium, 2 (12)
Clostridium spp., 2 (12)
Other, 7 (40)
Polymicrobial, 9 (35)
IAI by pathogens sensitive to ATB I, n (%) 50 (60) 20 (44) 10 (40)
IAI by pathogens sensitive to ATB 2, n (%) 66 (80) 27 (60) 12 (46)
Extent of infection, n (%) uIAI, 25 (16) cIAI, 129 (84)
Microbiological profile, n (%) Monomicrobial, 15 (60)
Clostridium spp., 9 (60)
E. coli, 2 (13)
E. faecium, 2 (13)
Other, 2 (13)
Polymicrobial, 10 (40)
Monomicrobial, 80 (62)
E. coli, 28 (35)
Klebsiella spp., 16 (20)
E. faecium, 8 (10)
Other, 28 (35)
Polymicrobial, 49 (38)
IAI by pathogens sensitive to ATB I, n (%) 5 (20) 75 (60)
IAI by pathogens sensitive to ATB 2, n (%) 17 (68) 88 (68)
Local of infection, n (%) Biliary Tract, 78 (51) Colon, 43 (28) Other, 33 (21)
Microbiological profile, n (%) Monomicrobial, 54 (69)
E. coli, 23 (43)
Klebsiella spp., 13 (24)
E. faecium, 7 (13)
Other, 35 (45)
Polymicrobial, 24 (31)
Monomicrobial, 21 (49)
Clostridium spp., 11 (52)
E. coli, 3 (14)
E. faecium, 2 (10)
Other, 5 (24)
Polymicrobial, 22 (51)
Monomicrobial, 20 (60)
Polymicrobial, 13 (40)
IAI by pathogens sensitive to ATB I, n (%) 42 (54) 20 (47) 18 (55)
IAI by pathogens sensitive to ATB 2, n (%) 51 (65) 32 (74) 22 (67)
ATB I, non-pseudomonal cephalosporin or ciprofloxacin plus metronidazole; ATB 2, piperacillin/tazobactam; CA-IAI, community-acquired intra-abdominal infection;
HCA-IAI, healthcare-associated intra-abdominal infection; HA-IAI, hospital-acquired intra-abdominal infection; uIAI, uncomplicated intra-abdominal infection; cIAI,
complicated intra-abdominal infection
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Prognostic risk factors in intra-abdominal infections
Factors significantly associated with hospital mortality
were: KPS score < 70, chronic kidney disease, the total
score of CCI, localization of infection, polymicrobial flora
and sensitivity to non-pseudomonal cephalosporin or cip-
rofloxacin plus metronidazole (Table 4).
In the multivariable analysis with the hospital mortal-
ity as the dependent variable, the final model retained
Table 4 Risk factors for hospital mortality
Total Hospital mortality p value Crude OR
Age≥ 70, n (%) 101 (66) 27 (27) 0.055 2.398
Male gender, n (%) 74 (48) 13 (18) 0.194 0.599
Karnofsky Performance Status Scale < 70, n (%) 112 (73) 20 (18) 0.042 0.435
Diabetes, n (%) 45 (29) 10 (22) 0.978 0.988
Liver disease, n (%) 14 (9) 4 (29) 0.512a 1.467
Solid tumour, n (%) 45 (29) 14 (31) 0.082 2.010
AIDS, n (%) 1 (1) 0 (0) 1.000a –
Chronic kidney disease, n (%) 26 (17) 10 (39) 0.027 2.708
Congestive heart failure, n (%) 11 (7) 0 (0) 0.124a –
Myocardial infarction, n (%) 10 (7) 1 (10) 0.461a 0.374
Chronic obstructive pulmonary disease, n (%) 10 (7) 3 (30) 0.693a 1.562
Peripheral vascular disease, n (%) 22 (14) 4 (18) 0.785a 0.756
Cerebrovascular accident/transient ischemic attack, n (%) 14 (9) 0 (0) 0.041a –
Dementia, n (%) 11 (7) 5 (46) 0.066a 3.276
Hemiplegia, n (%) 1 (1) 0 (0) 1.000a –
Connective tissue disease, n (%) 2 (1) 1 (50) 0.394a 3.606
Leukemia, n (%) 3 (2) 2 (67) 0.123a 7.437
Malignant lymphoma, n (%) 1 (0,6) 0 (0) 1.000a –
Peptic ulcer disease, n (%) 4 (3) 0 (0) 0.576a –
Total Score - Charlson Comorbidity Index, mean ± SD 5 ± 3 5 ± 3 0.045 0.866 per point
Residence in a long-term care facility or nursing home, n (%) 7 (5) 2 (29) 0.469a 1.484
Previous colonization/infection by DR pathogen, n (%) 29 (19) 4 (14) 0.322a 0.507
Previous antibiotic therapy, n (%) 39 (25) 11 (28) 0.286 1.571
Previous hospitalization, n (%) 82 (53) 19 (23) 0.727 1.146
Previous invasive procedures, n (%) 78 (51) 18 (23) 0.644 1.200
Initial antibiotic therapy adequate, n (%) 98 (64) 21 (21) 0.797 0.902
Polymicrobial flora, n (%) 59 (38) 18 (31) 0.049 2.168
Sensitive to ATB I, n (%) 80 (52) 12 (15) 0.030 0.417
Sensitive to ATB 2, n (%) 105 (68) 19 (18) 0.084 0.501
Positive blood cultures, n (%) 69 (57) 16 (15) 0.065 0.429
Post-operative infection, n (%) 19 (12) 3 (16) 0.570a 1.590
Place of acquisition – classification, n (%) 154 (100) 34 (22) 0.790 –
Community-acquired, n (%) 83 (54) 18 (22) – 1.000
Healthcare-associated, n (%) 45 (29) 9 (20) – 1.330
Hospital-acquired, n (%) 26 (17) 7 (27) – 1.474
Extent of infection – classification, n (%) 154 (100) 34 (22) 0.195a –
Uncomplicated, n (%) 25 (16) 3 (12) – 1.000
Complicated, n (%) 129 (84) 31 (24) – 2.320
aFisher’s exact test; AIDS acquired immune deficiency syndrome, DR drug-resistant, OR odds ratio, ATB I non-pseudomonal cephalosporin or ciprofloxacin plus
metronidazole, ATB 2 piperacillin/tazobactam
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age ≥ 70 with an adjusted OR (CI95%) = 4.677 (1.260–
17.358), solid tumour with an adjusted OR (CI95%) =
3.127 (1.183–8.266) and sensitivity to non-pseudomonal
cephalosporin or ciprofloxacin plus metronidazole with
an adjusted OR (CI95%) = 0.368 (0.138–0.980).
Discussion
The main finding of our study was the fact that none
of the existing classifications had a good discriminat-
ing power to identify IAIs caused by pathogens
sensitive to the current antibiotic treatment recom-
mendations. This supports the poor utility of the
existing classifications of IAI.
Independent risk factors for IAI caused by those patho-
gens was male gender, for which we cannot find an explan-
ation or similar results in other published studies; and
previous invasive procedures in the last year, which were
associated with IAI caused by pathogens not sensitive to
the shorter antibiotic scheme recommended for CA-IAI,
which has also been enlightened by other studies that
linked previous invasive procedures with greater rates of
colonization and infection with MDR pathogens [18].
Caution should be taken when using antibiotic schemes
containing fluroquinolones due to its high potential to in-
duce resistance and its very high resistance rates.
An alternative antibiotic scheme for CA-IAI is pipera-
cillin/tazobactam, which is an antibiotic with a broader
spectrum. Postoperative infections were associated with
a higher sensitivity to this antibiotic therapy. This result
cannot be explained by this study or the literature
reviewed. Liver disease also showed an association with
increased sensitivity to this antibiotic therapy. Sargenti
et al. [34] revealed that patients with liver disease have
mainly HCA-IAIs and HA-IAIS, which are often caused
by bacteria resistant to commonly used antibiotics, pi-
peracillin/tazobactam might be an option for this group
of patients [35].
Our data revealed that age ≥ 70 years was associated to
an increased hospital mortality, which is also supported by
the conclusions of other studies [15]. Higher age was also
connected, by many studies, to a greater prevalence of DR
pathogens, which has been implicated in an augmented
mortality rate [36–38]. Solid tumour was the comorbidity
that presented a connection with greater mortality, which
can be clarified by the higher prevalence of DR pathogens
that will result in an increased mortality rate [12, 36–38].
Patients with pathogens sensitive to non-pseudomonal
cephalosporin or ciprofloxacin plus metronidazole had an
associated lower hospital mortality, in this study. This
antibiotic scheme recommended for community-acquired
infections is the shortest spectrum one, pathogens sensi-
tive to this regimen are less resistant, having adequate
antibiotic therapy more frequently and causing infection
with lower severity, which can explain this association.
The total score of CCI was associated with increased
hospital mortality in accordance with the study by
Montravers et al. [15], that also revealed that the pres-
ence of one or more comorbidities had a predictive value
for hospital mortality.
In our study, most of the patients had blood cultures
taken (79%) and more than half were positive (57%),
which is similar to the results of Krobot et al. [21] (43%),
but considerably higher than the data observed by
Montravers et al. [15] (6%). Microbiological cultures, in-
cluding blood cultures, in IAIs are extremely important
to establish an adequate antibiotic therapy and should
be collected in every patient with IAI [3, 9, 12].
The distribution of isolated pathogens, in our study,
was identical to other reports, being Escherichia coli
the most frequent, independently of the classification
used [5, 15, 21, 39–41]. The prevalence of monomi-
crobial IAIs (62%) was much superior in comparison
to the studies by Claridge et al. [41] (41%) and Shah
et al. [42] (33%).
In our study the rate of inadequate antibiotic therapy
(36%) was within the range described in similar studies:
between 13 and 44% [21]. and it was not associated with
increased hospital mortality which was also observed by
Montravers et al. [15], but opposed to other several
studies [5, 13, 30]. Timing and adequacy of source con-
trol are recognized as major prognostic factors and those
were not targeted in our study and might explain this
finding.
The hospital mortality observed in this study is higher
than the described by Sartelli et al. [40] (22% vs. 11%),
but comparable to the results presented by Montravers
et al. [15]: 22% vs. 24% in CA-IAIs; 20% in HCA-IAIs
and 27% vs. 23% in nosocomial IAIs.
Our study has some limitations. Firstly, since it is a
single-centred study, the analysis was based on local data
and resistance patterns. Being a retrospective study, data
collection was limited to the existing records. Although
all variables thought to be relevant were collected in the
present study, there is always the possibility of additional
variables not considered here to be linked to the out-
come studied. Therefore, the results of this study must
be interpreted prudently.
We have not found studies that investigated the dis-
crimination of different classifications of IAI on the
selection of the best antibiotic therapy, so we assume
that our results could be of value to the clinicians in
the field.
Conclusions
In our study, none of the classifications revealed good
accuracy in determining infection by a pathogen sensi-
tive to current treatment guidelines, although gender,
comorbidities (namely chronic liver disease, previous
Silva-Nunes and Cardoso BMC Infectious Diseases          (2019) 19:980 Page 7 of 9
invasive procedures and post-operative infections) were
significantly associated with sensitivity to those antibiotic
schemes.
A new classification of IAI that includes patient’s risk
factors might have a greater potential in distinguish IAIs
by sensitive pathogens allowing a better choice of em-
piric antibiotic therapy, tailored to individual patient
needs with the minimum selective pressure.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12879-019-4604-0.
Additional file 1. ICD-9 selected codes. Selected codes of the
international statistical classification of diseases and related health problems
9th revision (ICD-9) to achieve the first selection of patients.
Additional file 2. Case report form. The case report form created and
used to collect the data from the final selection of patients.
Abbreviations
AIDS: Acquired immune deficiency syndrome; ATB 1: Non-pseudomonal
cephalosporin or ciprofloxacin plus metronidazole; ATB 2: Piperacillin/
tazobactam; ATB: Antibiotic; AUROC: Area under receiver operating
characteristics; CA-IAI: Community-acquired intra-abdominal infection;
CCI: Charlson Comorbidity Index; CHUP: Centro Hospitalar Universitário do
Porto; CI95%: 95% Confidence interval; cIAI: Complicated intra-abdominal In-
fection; DR: Drug-resistant; HA-IAI: Hospital-acquired intra-abdominal infec-
tion; HCA-IAI: Healthcare-associated intra-abdominal infection; IAI: Intra-
abdominal infection; ICD-9: International Statistical Classification of Diseases
and Related Health Problems 9th revision; IQR: Inter-quartile range;
KPS: Karnofsky Performance Status Scale; MDR: Multidrug-resistant; OR: Odds
ratio; ROC: Receiver operating characteristics; SD: Standard deviation;
SPSS: Statistical Package for the Social Sciences; uIAI: Uncomplicated intra-
abdominal infection
Acknowledgements
None.
Authors’ contributions
JSN and TC were responsible for study concept and design. JSN acquired
the data. JSN and TC were responsible for analysis and interpretation of data.
JSN was responsible for drafting the manuscript. All authors participated in
the analysis and interpretation of the data, clinical revision of the manuscript
and final approval of the version to be published.
Funding
No funding was obtained for this study.
Availability of data and materials
The datasets generated and analysed during the current study are not
publicly available since they are currently in use for other studies, but are
available from the corresponding author on reasonable request.
Ethics approval and consent to participate
The study was approved by the local ethics committee, Departamento de
Ensino, Formação e Investigação (DEFI) of Centro Hospitalar Universitário do
Porto (CHUP) - ref. 2017.226(195-DEFI/187-CES). The need for consent was
waived by the local ethics committee and patient data was de-identified.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Author details
1Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto
(ICBAS-UP), Rua de Jorge Viterbo Ferreira n.º 228, Porto 4050-313, Portugal.
2Intensive Care Unit, Unidade de Cuidados Intensivos Polivalente, Hospital de
Santo António - Centro Hospitalar Universitário do Porto (HSA-CHUP), Largo
Prof. Abel Salazar, Porto 4099-001, Portugal.
Received: 22 July 2019 Accepted: 29 October 2019
References
1. Lopez N, Kobayashi L, Coimbra R. A comprehensive review of abdominal
infections. World J Emerg Surg. 2011;6:7.
2. Lee YR, et al. Complicated intra-abdominal infections: the old antimicrobials
and the new players. Drugs. 2015;75(18):2097–117.
3. Montravers P, et al. Guidelines for management of intra-abdominal
infections. Anaesth Crit Care Pain Med. 2015;34(2):117–30.
4. Hoffmann C, et al. Treatment Modalities and Antimicrobial Stewardship
Initiatives in the Management of Intra-Abdominal Infections. Antibiotics
(Basel). 2016;5(1). https://doi.org/10.3390/antibiotics5010011.
5. Huang LL, et al. Guideline-concordant versus discordant antimicrobial
therapy in patients with community-onset complicated intra-abdominal
infections. Infect Control Hosp Epidemiol. 2016;37(7):855–8.
6. Sartelli M, et al. Antimicrobials: a global alliance for optimizing their rational
use in intra-abdominal infections (AGORA). World J Emerg Surg. 2016;11:33.
7. Blot S, De Waele JJ, Vogelaers D. Essentials for selecting antimicrobial
therapy for intra-abdominal infections. Drugs. 2012;72(6):e17–32.
8. Menichetti F, Sganga G. Definition and classification of intra-abdominal
infections. J Chemother. 2009;21(Suppl 1):3–4.
9. Sartelli M, et al. 2013 WSES guidelines for management of intra-abdominal
infections. World J Emerg Surg. 2013;8(1):3.
10. Sartelli M. A focus on intra-abdominal infections. World J Emerg Surg.
2010;5:9.
11. De Simone B, et al. Benefits of WSES guidelines application for the
management of intra-abdominal infections. World J Emerg Surg. 2015;10:18.
12. Sartelli M, et al. Antimicrobial management of intra-abdominal infections:
literature's guidelines. World J Gastroenterol. 2012;18(9):865–71.
13. Solomkin JS, et al. Diagnosis and management of complicated intra-
abdominal infection in adults and children: guidelines by the surgical
infection society and the Infectious Diseases Society of America. Clin Infect
Dis. 2010;50(2):133–64.
14. Solomkin JS, et al. Guidelines for the selection of anti-infective agents
for complicated intra-abdominal infections. Clin Infect Dis. 2003;37(8):
997–1005.
15. Montravers P, et al. Clinical and microbiological profiles of community-
acquired and nosocomial intra-abdominal infections: results of the
French prospective, observational EBIIA study. J Antimicrob Chemother.
2009;63(4):785–94.
16. Sartelli M, et al. Complicated intra-abdominal infections in Europe: a
comprehensive review of the CIAO study. World J Emerg Surg. 2012;7(1):36.
17. Garner, J.S., et al., [CDC definitions for nosocomial infections 1988]. Z Arztl
Fortbild (Jena), 1991 85(17): p. 818–27.
18. Cardoso T, et al. Classification of healthcare-associated infection: a
systematic review 10 years after the first proposal. BMC Med. 2014;12:40.
19. Friedman ND, et al. Health care--associated bloodstream infections in adults:
a reason to change the accepted definition of community-acquired
infections. Ann Intern Med. 2002;137(10):791–7.
20. Guilbart M, et al. Compliance with an empirical antimicrobial protocol
improves the outcome of complicated intra-abdominal infections: a
prospective observational study. Br J Anaesth. 2016;117(1):66–72.
21. Krobot K, et al. Effect of inappropriate initial empiric antibiotic therapy on
outcome of patients with community-acquired intra-abdominal infections
requiring surgery. Eur J Clin Microbiol Infect Dis. 2004;23(9):682–7.
22. Davey PG, Marwick C. Appropriate vs. inappropriate antimicrobial therapy.
Clin Microbiol Infect. 2008;14(Suppl 3):15–21.
23. Mazuski JE, et al. The surgical infection society guidelines on antimicrobial
therapy for intra-abdominal infections: an executive summary. Surg Infect.
2002;3(3):161–73.
24. Sartelli M, et al. WSES consensus conference: guidelines for first-line
management of intra-abdominal infections. World J Emerg Surg. 2011;6:2.
Silva-Nunes and Cardoso BMC Infectious Diseases          (2019) 19:980 Page 8 of 9
25. Yellin AE, et al. The role of Pseudomonas species in patients treated with
ampicillin and Sulbactam for gangrenous and perforated appendicitis. Surg
Gynecol Obstet. 1985;161(4):303–7.
26. Mosdell DM, et al. Antibiotic treatment for surgical peritonitis. Ann Surg.
1991;214(5):543–9.
27. Berne TV, et al. Antibiotic management of surgically treated gangrenous or
perforated appendicitis. Comparison of gentamicin and clindamycin versus
cefamandole versus cefoperazone. Am J Surg. 1982;144(1):8–13.
28. Falagas ME, et al. Risk factors leading to clinical failure in the treatment of
intra-abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis.
1996;15(12):913–21.
29. Sturkenboom MC, et al. Inappropriate initial treatment of secondary intra-
abdominal infections leads to increased risk of clinical failure and costs. Br J
Clin Pharmacol. 2005;60(4):438–43.
30. Montravers P, et al. Emergence of antibiotic-resistant bacteria in cases of
peritonitis after intraabdominal surgery affects the efficacy of empirical
antimicrobial therapy. Clin Infect Dis. 1996;23(3):486–94.
31. Feiring E, Walter AB. Antimicrobial stewardship: a qualitative study of the
development of national guidelines for antibiotic use in hospitals. BMC
Health Serv Res. 2017;17(1):747.
32. Karnofsky, D.A. and J.H. Burchenal, The Clinical Evaluation of
Chemotherapeutic Agents in Cancer. C. M. MacLeod, Ed., 1949(Evaluation of
Chemotherapeutic Agents, Columbia University Press): p. 196.
33. Charlson ME, et al. A new method of classifying prognostic comorbidity in
longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):
373–83.
34. Sargenti K, et al. Healthcare-associated and nosocomial bacterial
infections in cirrhosis: predictors and impact on outcome. Liver Int.
2015;35(2):391–400.
35. Merli M, et al. An empirical broad spectrum antibiotic therapy in health-
care-associated infections improves survival in patients with cirrhosis: a
randomized trial. Hepatology. 2016;63(5):1632–9.
36. Christou NV, et al. Management of intra-abdominal infections. The case for
intraoperative cultures and comprehensive broad-spectrum antibiotic
coverage. The Canadian intra-abdominal infection study group. Arch Surg.
1996;131(11):1193–201.
37. Barie PS, et al. A randomized, double-blind clinical trial comparing
cefepime plus metronidazole with imipenem-cilastatin in the treatment
of complicated intra-abdominal infections. Cefepime intra-abdominal
infection study group. Arch Surg. 1997;132(12):1294–302.
38. Hopkins JA, Lee JC, Wilson SE. Susceptibility of intra-abdominal isolates
at operation: a predictor of postoperative infection. Am Surg. 1993;
59(12):791–6.
39. Zhang S, Huang W. Epidemiological study of community- and hospital-
acquired intraabdominal infections. Chin J Traumatol. 2015;18(2):84–9.
40. Sartelli M, et al. Complicated intra-abdominal infections worldwide: the
definitive data of the CIAOW study. World J Emerg Surg. 2014;9:37.
41. Claridge JA, et al. Bacterial species-specific hospital mortality rate for intra-
abdominal infections. Surg Infect. 2014;15(3):194–9.
42. Shah PM, et al. Do Polymicrobial intra-abdominal infections have worse
outcomes than Monomicrobial intra-abdominal infections? Surg Infect.
2016;17(1):27–31.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Silva-Nunes and Cardoso BMC Infectious Diseases          (2019) 19:980 Page 9 of 9
